In addition, we demonstrated that the gain of PIK3CA mutation may lead to less sensitivity and even resistance to gefitinib in EGFR mutation NSCLC cell lines, due to its activation of PI3K/AKT signal pathway. The gene discussed is PIK3CA; the disease is non-small cell lung carcinoma.